Since iBio Inc. (NYSEAMERICAN:IBIO) and Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of both companies.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Y-mAbs Therapeutics Inc.||23||0.00||N/A||-1.95||0.00|
Table 1 demonstrates iBio Inc. and Y-mAbs Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 provides us the return on assets, net margins and return on equity of both businesses.
|Net Margins||Return on Equity||Return on Assets|
|Y-mAbs Therapeutics Inc.||0.00%||0%||0%|
iBio Inc. and Y-mAbs Therapeutics Inc. Recommendations and Ratings are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Y-mAbs Therapeutics Inc.||0||0||1||3.00|
Competitively Y-mAbs Therapeutics Inc. has an average price target of $36, with potential upside of 39.43%.
Insider and Institutional Ownership
iBio Inc. and Y-mAbs Therapeutics Inc. has shares held by institutional investors as follows: 8.1% and 34%. Insiders held 45.24% of iBio Inc. shares. Comparatively, 51.22% are Y-mAbs Therapeutics Inc.’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Y-mAbs Therapeutics Inc.||-2.7%||-2.14%||-1.37%||10.36%||0%||9.98%|
For the past year iBio Inc. has -11.02% weaker performance while Y-mAbs Therapeutics Inc. has 9.98% stronger performance.
Y-mAbs Therapeutics Inc. beats iBio Inc. on 6 of the 8 factors.
iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.